PODD enters the back half of August in an uncomfortable spot — down 12% over the past month, with analysts still scrambling to reset expectations after a sharp post-earnings sell-off earlier in the month, and the CEO quietly buying stock near multi-year lows.
The most striking development in recent weeks is how aggressively short sellers have pulled back. Short interest has fallen 30% over the past month, dropping from above 5 million shares to around 3.5 million — now at exactly 5% of the free float. That retreat is consistent with a stock that has already done most of its damage; bears who had conviction at higher prices have largely covered. The ORTEX short score confirms the easing pressure, sliding from 40.0 on August 12 to 36.9 now — a meaningful decline that suggests the short thesis is losing momentum rather than building. Borrow remains trivially cheap at 0.54%, and availability is exceptionally loose at nearly 9,500% of short interest, meaning there is essentially no constraint on new shorts if sentiment were to turn. The lending market, in other words, is not the story.
Options positioning is mildly more cautious than usual but far from extreme. The put/call ratio has climbed to 0.83 against a 20-day average of 0.69 — about 0.6 standard deviations above the mean. That is a modest tilt toward protection, not a genuine flight to hedges. What is notable is the trajectory: through late July the PCR was running below 0.36 consistently; the shift above 0.80 tracks almost exactly with the August 5 earnings drop and the wave of analyst target cuts that followed. Caution has crept in, but it has not escalated further this week.
The Street reaction to Q2 results was dramatic. Ten analysts cut price targets on August 6, with JP Morgan and Wells Fargo both downgrading outright — JP Morgan to Neutral from Overweight with a target reset to $152 from $275, Wells Fargo to Equal-Weight from Overweight at $144 from $255. Leerink Partners also downgraded to Market Perform. The remainder maintained ratings but slashed targets by between $25 and $110. The consensus still leans buy — 11 buys, 4 outperforms, 10 holds — but the mean target of $172 now sits only 20% above the current price of $143, a gap that feels thinner given how aggressively targets were reset just three weeks ago. The bull case rests on Omnipod 5's international momentum and improving commercial execution; the bear case centres on US Type 2 utilisation decay, management credibility after a guidance miss, and intensifying tubeless pump competition. EPS momentum factor scores rank in the 21st percentile on a forward basis and the 23rd on a 30-day basis — weak across the board.
The most interesting signal this week is insider behaviour. CEO Ashley McEvoy purchased 1,100 shares on August 21 at $147.47 — a $162,000 buy that came just two weeks after the earnings collapse. That follows a cluster of board-level buying in early June, when the Independent Chairman paid nearly $500,000 and a director added $400,000 worth of shares, both near the $143–$144 level. Net insider activity over the past 90 days is positive at roughly $1.16 million. It is a small float of capital in absolute terms, but the pattern — executives buying at current prices while analysts reset targets near those same levels — is worth flagging. The stock is trading right at the floor where both insiders and several newly reset analyst targets converge.
Among correlated peers, COO fell 3.6% on the week and ATEC shed 2.1%, suggesting broader medtech weakness rather than PODD-specific pressure. DXCM, the closest diabetes-adjacent name, was off 0.5%. The next earnings event is not until November 5, leaving roughly ten weeks for the commercial narrative — US Type 2 retention, international growth, and any guidance revision — to either validate or further undermine the post-August reset.
The question heading into Q3 is whether the convergence of insider buying, short covering, and analyst target resets near the $143–$150 zone marks genuine stabilisation, or simply a pause before the fundamental debate over US utilisation trends reasserts itself.
See the live data behind this article on ORTEX.
Open PODD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
